Drug Profile
Research programme: meningococcus vaccine - Novartis
Latest Information Update: 11 Aug 2011
Price :
$50
*
At a glance
- Originator National Research Council Canada; University of Oxford
- Developer Novartis Vaccines
- Class Vaccines
- Mechanism of Action Lipopolysaccharide modulators
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Meningococcal infections
Most Recent Events
- 11 Aug 2011 No development reported - Preclinical for Meningococcal infections in USA (Parenteral)
- 18 Dec 2008 Preclinical trials in Meningococcal infections in USA (Parenteral)